Auinash Kalsotra

Title: Auinash Kalsotra: Innovator in Myotonic Dystrophy Research

Introduction

Auinash Kalsotra is a prominent inventor based in Champaign, IL, who has made significant contributions to the field of myotonic dystrophy research. His innovative work focuses on developing therapeutic strategies to address the underlying causes of this genetic disorder.

Latest Patents

Kalsotra holds a patent for a multivalent ligand designed to target myotonic dystrophy. This invention addresses the abnormally long r(CUG)n repeat expansion, which is believed to be the major cause of Myotonic dystrophy type 1 (DM1). The ligand binds to the muscleblind-like 1 (MBNL 1) protein, which plays a crucial role in RNA splicing. The rational design of oligomers with alternating bisamidine and melamine structures resulted in a strong binding affinity to the RNA target due to a multivalent effect. These oligomers demonstrated excellent activity in disrupting nuclear foci, reversing the mis-splicing of the IR minigene, and sabotaging toxic RNA biosynthesis. Furthermore, the oligomers showed promising results in DM1 models, rescuing the climbing ability of flies upon oral treatment.

Career Highlights

Kalsotra is affiliated with the University of Illinois, where he continues to advance his research in molecular biology and genetics. His work has garnered attention for its potential to transform the treatment landscape for myotonic dystrophy.

Collaborations

Some of Kalsotra's notable coworkers include Yugang Bai and Steven C. Zimmerman, who contribute to the collaborative efforts in his research endeavors.

Conclusion

Auinash Kalsotra's innovative work in developing a multivalent ligand for myotonic dystrophy showcases his commitment to addressing complex genetic disorders. His contributions have the potential to significantly impact the lives of those affected by this condition.